Ion channel drug discovery: Challenges and future directions

Future Medicinal Chemistry

Volumn 4, Issue 5, 2012, Pages 661-679

  Wickenden, A ^a   Priest, B ^b   Erdemli, G ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,4 DIHYDROXYPHENYL) N METHYLSERINE METHYL ESTER; ALPRAZOLAM; AM 101; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CE 224535; CHF 338; CNV 1014802; CX 171; CX 717; EFFIRMA; FARAMPATOR; FLUPIRTINE; GANAXOLONE; GLUTAMATE RECEPTOR ANTAGONIST; ICA 105665; INDANTADOL; ION CHANNEL; IRAMPANEL; IVACAFTOR; KALYDECO; MOTIVA; NEFIRACETAM; NERAMEXANE; OMEGA CONOTOXIN MVIIA; ORG 26576; PERAMPANEL; PLACEBO; POTASSIUM CHANNEL AFFECTING AGENT; RADIPRODIL; RETIGABINE; SODIUM CHANNEL BLOCKING AGENT; STACCATO; TALAMPANEL; TLN 4601; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; XALIPRODEN;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; BRAIN ISCHEMIA; CHRONIC PAIN; COUGHING; CYSTIC FIBROSIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EPILEPSY; FIBROMYALGIA; FRAGILE X SYNDROME; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR DEPRESSION; NEOPLASM; NEUROPATHIC PAIN; NONHUMAN; PAIN; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; STROKE; TINNITUS;

BIOLOGICAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION CHANNELS; LIGANDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859450561     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.4     Document Type: Review

References (122)

1. Sumikawa K, Houghton M, Smith JC, Bell L, Richards BM, Barnard EA. The molecular cloning and characterisation of cDNA coding for the a subunit of the acetylcholine receptor. Nucleic Acids Res. 10(19), 5809-5822 (1982).
2. Herz JM, Thomsen WJ, Yarbrough GG. Molecular approaches to receptors as targets for drug discovery. J. Recept. Signal Transduct. Res. 17(5), 671-776 (1997). (Pubitemid 27381429)
3. Dunlop J, Bowlby M, Peri R et al. Ion channel screening. Comb. Chem. High Throughput Screen 11(7), 514-522 (2008).
4. Tonstad S, Rollema H. Varenicline in smoking cessation. Expert Rev. Respir. Med. 4(3), 291-299 (2010).
5. Weisenberg JL, Wong M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr. Dis. Treat. 7(1), 409-414 (2011).
6. Doggrell SA. Intrathecal ziconotide for refractory pain. Expert Opin. Invest. Drugs 13(7), 875-877 (2004). (Pubitemid 39028936)
7. Opar A. Excitement mounts for first disease-modifying cystic fibrosis drugs. Nat. Rev. Drug Discov. 10(7), 479-480 (2011).
8. Krauss GL, Bar M, Biton V et al. Tolerability and safety of perampanel: Two randomized dose-escalation studies. Acta Neurol. Scand. 125(1), 8-15 (2011).
9. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010).
10. Borgeat A, Aguirre J. Update on local anesthetics. Curr. Opin. Anaesthesiol. 23(4), 466-471 (2010).
11. Pitt B. Diversity of calcium antagonists. Clin. Ther. 19(Suppl. A), 3-17 (1997).
12. Garty H, Rudy B, Karlish SJ. A simple and sensitive procedure for measuring isotope fluxes through ion-specific channels in heterogenous populations of membrane vesicles. J. Biol. Chem. 258(21), 13094-13099 (1983).
13. Maddox RW, Arnold WS, Dewell WM Jr. Extreme hyperkalemia associated with amiloride. South Med. J. 78(3), 365 (1985).
14. Christensen BM, Perrier R, Wang Q et al. Sodium and potassium balance depends on aENaC expression in connecting tubule. J. Am. Soc. Nephrol. 21(11), 1942-1951 (2010).
15. Jurkat-Rott K, Lerche H, Weber Y, Lehmann-Horn F. Hereditary channelopathies in neurology. Adv. Exp. Med. Biol. 686, 305-334 (2010).
16. Roberts JD, Gollob MH. The genetic and clinical features of cardiac channelopathies. Future Cardiol. 6(4), 491-506 (2010).
17. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Na(v)1.7 and human pain disorders. Trends Neurosci. 30(11), 555-563 (2007). (Pubitemid 350051424)
18. Cox JJ, Reimann F, Nicholas AK et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444(7121), 894-898 (2006). (Pubitemid 46024997)
19. Chadha V, Alon US. Hereditary renal tubular disorders. Semin. Nephrol. 29(4), 399-411 (2009).
20. Tobin MD, Tomaszewski M, Braund PS et al. Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population. Hypertension 51(6), 1658-1664 (2008).
21. Ji W, Foo JN, O'Roak BJ et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet. 40(5), 592-599 (2008). (Pubitemid 351601207)
22. Cao YQ. Voltage-gated calcium channels and pain. Pain 126(1-3), 5-9 (2006).
23. Kim D, Song I, Keum S et al. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking a (1G) T-Type Ca(2+) channels. Neuron 31(1), 35-45 (2001). (Pubitemid 32757087)
24. Kaczmarek LK. Non-conducting functions of voltage-gated ion channels. Nat. Rev. Neurosci. 7(10), 761-771 (2006). (Pubitemid 44435259)
25. Moosmang S, Haider N, Bruderl B, Welling A, Hofmann F. Antihypertensive effects of the putative T-Type calcium channel antagonist mibefradil are mediated by the L-Type calcium channel Cav1.2. Circ. Res. 98(1), 105-110 (2006). (Pubitemid 43970209)
26. Cha TJ, Ehrlich JR, Chartier D, Qi XY, Xiao L, Nattel S. Kir3-based inward rectifier potassium current: Potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 113(14), 1730-1737 (2006). (Pubitemid 43958465)
27. Herrington J, Zhou YP, Bugianesi RM et al. Blockers of the delayed-rectifier potassium current in pancreatic b-cells enhance glucose-dependent insulin secretion. Diabetes 55(4), 1034-1042 (2006). (Pubitemid 44100179)
28. Lu Q, An WF. Impact of novel screening technologies on ion channel drug discovery. Comb. Chem. High Throughput Screen 11(3), 185-194 (2008). (Pubitemid 351480892)
29. Terstappen GC, Roncarati R, Dunlop J, Peri R. Screening technologies for ion channel drug discovery. Future Med. Chem. 2(5), 715-730 (2010).
30. Stankovich L, Wicks D, Despotovski S, Liang D. Atomic absorption spectroscopy in ion channel screening. Assay Drug Dev. Technol. 2(5), 569-574 (2004). (Pubitemid 39619100)
31. Ransom RW, Stec NL. Inhibition of N-methyl-d-aspartate evoked sodium flux by MK-801. Brain Res. 444(1), 25-32 (1988). (Pubitemid 18071192)
32. Arranz E, Diaz JA, Vega S et al. Synthesis and pharmacological evaluation of 2, 3-dihydro-3-oxo-4H-Thieno[3,4-e][1,2,4]thiadiazine 1,1-dioxides as voltage-dependent calcium channel blockers. Eur. J. Med. Chem. 35(7-8), 751-759 (2000). (Pubitemid 30490283)
33. Cheng CS, Alderman D, Kwash J et al. A high-Throughput hERG assay with a new look. Drug Dev. Ind. Pharm. 28(2), 177-191 (2002).
34. Abbadie C, McManus OB, Sun SY et al. Analgesic effects of a substituted N-Triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J. Pharmacol. Exp. Ther. 334(2), 545-555 (2010).
35. Hansen KB, Mullasseril P, Dawit S et al. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-d-aspartate receptor antagonists. J. Pharmacol. Exp. Ther. 333(3), 650-662 (2010).
36. Lewis LM, Bhave G, Chauder BA et al. High-Throughput screening reveals a small-molecule inhibitor of the renal outer medullary potassium channel and Kir7.1. Mol. Pharmacol. 76(5), 1094-1103 (2009).
37. Felix JP, Williams BS, Priest BT et al. Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev. Technol. 2(3), 260-268 (2004). (Pubitemid 39069632)
38. Priest BT, Swensen AM, McManus OB. Automated electrophysiology in drug discovery. Curr. Pharm. Des. 13(23), 2325-2337 (2007). (Pubitemid 47317026)
39. Xia M, Imredy JP, Koblan KS, Bennett P, Connolly TM. State-dependent inhibition of L-Type calcium channels: Cell-based assay in high-Throughput format. Anal. Biochem. 327(1), 74-81 (2004). (Pubitemid 38367985)
40. Baxter DF, Kirk M, Garcia AF et al. A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J. Biomol. Screen 7(1), 79-85 (2002). (Pubitemid 34208865)
41. Zou B, Yu H, Babcock JJ et al. Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-á-go-go related gene potassium channels. Assay Drug Dev. Technol. 8(6), 743-754 (2010).
42. Clare JJ. Targeting ion channels for drug discovery. Discov. Med. 9(46), 253-260 (2010).
43. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol. Rev. 38(4), 321-416 (1986). (Pubitemid 17229059)
44. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73(1), 157-169 (2008). (Pubitemid 350294207)
45. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. 58(3), 591-600 (2000).
46. Li SX, Huang S, Bren N et al. Ligand-binding domain of an a7-nicotinic receptor chimera and its complex with agonist. Nat. Neurosci. 14(10), 1253-1259 (2011).
47. Large CH, Kalinichev M, Lucas A et al. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res. 85(1), 96-106 (2009).
48. Jarvis MF, Honore P, Shieh CC et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl Acad. Sci. USA 104(20), 8520-8525 (2007). (Pubitemid 47175520)
49. Sugioka N, Koyama H, Kawakubo M et al. Age-dependent alteration of the serum-unbound fraction of nicardipine, a calcium-channel blocker, in man. J. Pharm. Pharmacol. 48(12), 1327-1331 (1996). (Pubitemid 27035926)
50. Plum A, Muller LK, Jansen JA. The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma. Methods Find. Exp. Clin. Pharmacol. 22(3), 139-143 (2000). (Pubitemid 30413252)
51. Gever JR, Soto R, Henningsen RA et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br. J. Pharmacol. 160(6), 1387-1398 (2010).
52. Ratliff KS, Petrov A, Eiermann GJ et al. An automated electrophysiology serum shift assay for K(V) channels. Assay Drug Dev. Technol. 6(2), 243-253 (2008). (Pubitemid 351670381)
53. Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage-dependent inhibition of Type 2A Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol. Pharmacol. 40(5), 756-765 (1991).
54. Catterall WA. Molecular properties of brain sodium channels: An important target for anticonvulsant drugs. Adv. Neurol. 79, 441-456 (1999).
55. Hildebrand ME, Smith PL, Bladen C et al. A novel slow-inactivation- specific ion channel modulator attenuates neuropathic pain. Pain 152(4), 833-843 (2011).
56. Capelli AM, Castelletti L, Salvagno C et al. Identification of novel a7 nAChR positive allosteric modulators with the use of pharmacophore in silico screening methods. Bioorg. Med. Chem. Lett. 20(15), 4561-4565 (2010).
57. Dinklo T, Shaban H, Thuring JW et al. Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-Thiazoleme thanol (JNJ-1930942), a novel positive allosteric modulator of the {a}7 nicotinic acetylcholine receptor. J. Pharmacol. Exp. Ther. 336(2), 560-574 (2011).
58. Lee CH, Zhu C, Malysz J et al. a4b2 neuronal nicotinic receptor positive allosteric modulation: An approach for improving the therapeutic index of a4b2 nAChR agonists in pain. Biochem. Pharmacol. 82(8), 959-966 (2011).
59. Zhu CZ, Chin CL, Rustay NR et al. Potentiation of analgesic efficacy but not side effects: Co-administration of an a4b2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochem. Pharmacol. 82(8), 967-976 (2011).
60. Swanson DM, Dubin AE, Shah C et al. Identification and biological evaluation of 4-(3-Trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-Trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 48(6), 1857-1872 (2005). (Pubitemid 40396317)
61. Lipscombe D, Raingo J. Alternative splicing matters: N-Type calcium channels in nociceptors. Channels (Austin) 1(4), 225-227 (2007).
62. Ermolinsky BS, Skinner F, Garcia I et al. Upregulation of STREX splice variant of the large conductance Ca2+-activated potassium (BK) channel in a rat model of mesial temporal lobe epilepsy. Neurosci. Res. 69(1), 73-80 (2010).
63. Nimigean CM. A radioactive uptake assay to measure ion transport across ion channel-containing liposomes. Nat. Protoc. 1(3), 1207-1212 (2006).
64. Schieder M, Rotzer K, Bruggemann A, Biel M, Wahl-Schott C. Planar patch clamp approach to characterize ionic currents from intact lysosomes. Sci. Signal 3(151), pl3 (2010).
65. Nishimune H. Transsynaptic channelosomes: Non-conducting roles of ion channels in synapse formation. Channels (Austin) 5(5), 432-439 (2011).
66. Feinshreiber L, Singer-Lahat D, Friedrich R et al. Non-conducting function of the Kv2.1 channel enables it to recruit vesicles for release in neuroendocrine and nerve cells. J. Cell. Sci. 123(Part 11), 1940-1947 (2010).
67. + currents in neurons. J. Physiol. 586(Pt 23), 5609-5623 (2008).
68. Meadows LS, Isom LL. Sodium channels as macromolecular complexes: Implications for inherited arrhythmia syndromes. Cardiovasc. Res. 67(3), 448-458 (2005). (Pubitemid 41019552)
69. Wang Y, Brittain JM, Jarecki BW et al. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J. Biol. Chem. 285(33), 25296-25307 (2010).
70. Ameen C, Strehl R, Bjorquist P, Lindahl A, Hyllner J, Sartipy P. Human embryonic stem cells: Current technologies and emerging industrial applications. Crit. Rev. Oncol. Hematol. 65(1), 54-80 (2008). (Pubitemid 350225669)
71. Sartipy P, Bjorquist P, Strehl R, Hyllner J. The application of human embryonic stem cell technologies to drug discovery. Drug Discov. Today 12(17-18), 688-699 (2007). (Pubitemid 47362783)
72. Liu Q, Huang H, Cai H et al. Embryonic stem cells as a novel cell source of cell-based biosensors. Biosens. Bioelectron 22(6), 810-815 (2007). (Pubitemid 44914046)
73. Stastna M, Abraham MR, Van Eyk JE. Cardiac stem/progenitor cells, secreted proteins, and proteomics. FEBS Lett. 583(11), 1800-1807 (2009).
74. Dick E, Rajamohan D, Ronksley J, Denning C. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem. Soc. Trans 38(4), 1037-1045 (2010).
75. McNeish J, Roach M, Hambor J et al. High-Throughput screening in embryonic stem cell-derived neurons identifies potentiators of a-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-Type glutamate receptors. J. Biol. Chem. 285(22), 17209-17217 (2010).
76. He JQMJ, Anson B. Use of pluripotent stem cell-derived cardiomyocytes to understand mechanisms of cardiotoxic compounds. Cell Notes 23, 10-12 (2009).
77. Cezar GG. Can human embryonic stem cells contribute to the discovery of safer and more effective drugs? Curr. Opin. Chem. Biol. 11(4), 405-409 (2007). (Pubitemid 47302846)
78. Asai Y, Tada M, Otsuji TG, Nakatsuji N. Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: An ideal hybrid model assay for drug development. Curr. Stem Cell Res. Ther. 5(3), 227-232 (2010).
79. Jensen J, Hyllner J, Bjorquist P. Human embryonic stem cell technologies and drug discovery. J. Cell. Physiol. 219(3), 513-519 (2009).
80. Habib M, Caspi O, Gepstein L. Human embryonic stem cells for cardiomyogenesis. J. Mol. Cell. Cardiol. 45(4), 462-474 (2008).
81. Yazawa M, Hsueh B, Jia X et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471(7337), 230-234 (2011).
82. Wu J, Shih HP, Vigont V et al. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. Chem. Biol. 18(6), 777-793 (2011).
83. Sanz LM, Jimenez-Diaz MB, Crespo B et al. Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrob. Agents Chemother. 55(12), 5740-5745 (2011).
84. McLaughlin J, Markovtsov V, Li H et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J. Cancer Res. Clin. Oncol. 136(1), 99-113 (2010).
85. Saxe JP, Wu H, Kelly TK et al. A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem. Biol. 14(9), 1019-1030 (2007). (Pubitemid 47404902)
86. Roos J, DiGregorio PJ, Yeromin AV et al. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J. Cell Biol. 169(3), 435-445 (2005). (Pubitemid 40686694)
87. Zhang SL, Yeromin AV, Zhang XH et al. Genome-wide RNAi screen of Ca(2+) influx identifies genes that regulate Ca(2+) release-activated Ca(2+) channel activity. Proc. Natl Acad. Sci. USA 103(24), 9357-9362 (2006). (Pubitemid 43902581)
88. Coste B, Mathur J, Schmidt M et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science 330(6000), 55-60 (2010).
89. Mayr LM, Bojanic D. Novel trends in high-Throughput screening. Curr. Opin. Pharmacol. 9(5), 580-588 (2009).
90. Teichert RW, Olivera BM. Natural products and ion channel pharmacology. Future Med. Chem. 2(5), 731-744 (2010).
91. Molinari G. Natural products in drug discovery: Present status and perspectives. Adv. Exp. Med. Biol. 65(5), 13-27 (2009).
92. Harvey AL. Natural products in drug discovery. Drug Discov. Today 13(19-20), 894-901 (2008).
93. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat. Rev. Drug Discov. 8(1), 69-85 (2009).
94. Escoubas P, King GF. Venomics as a drug discovery platform. Expert Rev. Proteomics 6(3), 221-224 (2009).
95. Chi V, Pennington MW, Norton RS et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 59(4), 529-546 (2011).
96. Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 58(21), 4871-4879 (1998). (Pubitemid 28503684)
97. Buti M, Esteban R. 1990-2010: Two decades of interferon-based therapy. Clin. Liver Dis. 15(3), 473-482 (2011).
98. Mochly-Rosen D, Fuchs S. Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site. Biochemistry 20(20), 5920-5924 (1981).
99. Watters D, Maelicke A. Organization of ligand binding sites at the acetylcholine receptor: A study with monoclonal antibodies. Biochemistry 22(8), 1811-1819 (1983). (Pubitemid 13093448)
100. Buell G, Chessell IP, Michel AD et al. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92(10), 3521-3528 (1998). (Pubitemid 28525175)
101. Zhou BY, Ma W, Huang XY. Specific antibodies to the external vestibule of voltage-gated potassium channels block current. J. Gen. Physiol. 111(4), 555-563 (1998). (Pubitemid 28193276)
102. Xu SZ, Zeng F, Lei M et al. Generation of functional ion-channel tools by E3 targeting. Nat. Biotechnol. 23(10), 1289-1293 (2005). (Pubitemid 41486857)
103. Naylor J, Milligan CJ, Zeng F, Jones C, Beech DJ. Production of a specific extracellular inhibitor of TRPM3 channels. Br. J. Pharmacol. 155(4), 567-573 (2008).
104. Klionsky L, Tamir R, Holzinger B et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid Type 1 blocks channel activation. J. Pharmacol. Exp. Ther. 319(1), 192-198 (2006). (Pubitemid 44455123)
105. Gomez-Varela D, Zwick-Wallasch E, Knotgen H et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res. 67(15), 7343-7349 (2007). (Pubitemid 47206564)
106. Thiel KA. Structure-aided drug design's next generation. Nat. Biotechnol. 22(5), 513-519 (2004). (Pubitemid 38585899)
107. + conduction and selectivity. Science 280(5360), 69-77 (1998). (Pubitemid 28169082)
108. Jamieson C, Maclean JK, Brown CI et al. Structure based evolution of a novel series of positive modulators of the AMPA receptor. Bioorg. Med. Chem. Lett. 21(2), 805-811 (2011).
109. de Groot MJ. Understanding ion channels using computational approaches. Future Med. Chem. 2(5), 697-701 (2010).
110. Vinik AI, Tuchman M, Safirstein B et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain 128(1-2), 169-179 (2007). (Pubitemid 46216610)
111. Rao RD, Flynn PJ, Sloan JA et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A Phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112(12), 2802-2808 (2008). (Pubitemid 351969227)
112. Ataga KI, Reid M, Ballas SK et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: A Phase 3 randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br. J. Haematol. 153(1), 92-104 (2011).
113. Chizh BA, O'Donnell MB, Napolitano A et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132(1-2), 132-141 (2007). (Pubitemid 47494566)
114. Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Annu. Rheum. Dis. doi:10.1136/ard.2010.143578 (2011) (Epub ahead of print).
115. Ataga KI, Smith WR, De Castro LM et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 111(8), 3991-3997 (2008).
116. Stehouwer JS, Goodman MM. Fluorine-18 radiolabeled PET tracers for imaging monoamine transporters: Dopamine, serotonin, and norepinephrine. PET Clin. 4(1), 101-128 (2009).
117. Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. Br. J. Pharmacol. 157(8), 1301-1317 (2009).
118. Bursi R, Erdemli G, Campbell R et al. Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology (Berl.) 218(4), 713-724 (2011).
119. Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: An imperative for breakthrough therapies. Nat. Med. 15(5), 502-507 (2009).
120. Ward SE, Bax BD, Harries M. Challenges for and current status of research into positive modulators of AMPA receptors. Br. J. Pharmacol. 160(2), 181-190 (2010).
121. Norman P. Ion Channel Modulator Pipelines: Targets and Agents in Development. Cambridge Healthtech Institute, Needham, MA, USA (2009).
122. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: Newly approved and developmental agents. CNS Drugs 25(2), 89-107 (2011).